REVB:NASDAQRevelation Biosciences, Inc. Analysis
Data as of 2026-07-05 - not real-time
$1.08
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Technical outlook: The stock is trading below its 20‑day and 50‑day moving averages and well under the 200‑day average, signalling a bearish momentum. RSI sits near the midpoint of the scale, while the MACD histogram has turned positive but the MACD line remains below the signal, confirming lingering weakness. Price is hugging a clear support zone just above $0.95 and faces resistance near $1.11, with volume trending downwards and beta modestly above 1, indicating higher than market volatility.
Fundamental picture: The company reports zero revenue and negative earnings, with a negative PE and a very low price‑to‑book ratio, suggesting the market is pricing in severe execution risk. Cash on hand exceeds debt, but operating and free cash flow are deeply negative, and margins are non‑existent. The upside potential implied by the model exceeds 1,600%, yet the downside risk is substantial given the high 30‑day volatility (>60%) and a historic max drawdown over 90%.
Fundamental picture: The company reports zero revenue and negative earnings, with a negative PE and a very low price‑to‑book ratio, suggesting the market is pricing in severe execution risk. Cash on hand exceeds debt, but operating and free cash flow are deeply negative, and margins are non‑existent. The upside potential implied by the model exceeds 1,600%, yet the downside risk is substantial given the high 30‑day volatility (>60%) and a historic max drawdown over 90%.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish technical positioning below key moving averages
- Decreasing volume and high short‑term volatility
- Negative cash flow and lack of revenue
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential clinical‑stage catalysts that could shift sentiment
- Sufficient cash runway to fund near‑term trials
- Continued valuation pressure from ongoing losses
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- Low price‑to‑book ratio offering a deep value cushion
- Strategic focus on innate‑immune modulation with unmet medical need
- Potential upside if lead candidate achieves regulatory approval
Key Metrics & Analysis
Financial Health
P/E Ratio-0.4
ROE-124.41%
ROA-66.19%
Debt/Equity5.84
P/B Ratio0.3
Op. Cash Flow$-8690025
Free Cash Flow$-5157217
Industry P/E26.4
Technical Analysis
TrendBearish
RSI55.0
Support$0.95
Resistance$1.11
MA 20$1.02
MA 50$1.05
MA 200$2.66
MACDBullish
VolumeDecreasing
Fear & Greed Index93.2
Valuation
Target Price$19.25
Upside/Downside1682.41%
GradeUndervalued
TypeValue
Risk Assessment
Beta1.13
Volatility64.25%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.